Rabbit polyclonal antilymphocyte globulin used for in vivo T-cell depletion to reduce graft-versus-host disease risk.
Rabbit polyclonal IgG against multiple human T‑cell surface antigens (e.g., CD2, CD3, CD4, CD8, HLA) that depletes T lymphocytes via complement-dependent cytotoxicity, Fc-mediated ADCC/phagocytosis, and apoptosis, producing in vivo T‑cell immunosuppression to reduce GVHD risk.
rATG contains antibodies that bind HLA-DR on the cell surface and trigger complement-dependent lysis and Fc-mediated ADCC/phagocytosis, causing apoptosis/lysis of the targeted cells.
Arlocabtagene autoleucel (BMS-986393; arlo-cel) is an autologous anti-GPRC5D CAR T-cell therapy that redirects patient T cells to recognize and kill GPRC5D-expressing myeloma cells.
Autologous T cells engineered to express a chimeric antigen receptor targeting GPRC5D. After reinfusion, the CAR T cells bind GPRC5D on myeloma cells, become activated, proliferate, release cytotoxic mediators and cytokines, and selectively lyse GPRC5D-expressing tumor cells.
Anti-GPRC5D CAR T cells bind GPRC5D on target cells, become activated, and kill them via T‑cell cytotoxic mechanisms (perforin/granzyme-mediated apoptosis and related effector functions).
Alnuctamab (BMS-986349; CC-93269) is a BCMA×CD3 bispecific T-cell–engaging antibody that links CD3 on T cells to BCMA on myeloma cells to trigger T-cell cytotoxicity.
Bispecific T‑cell–engaging antibody that binds BCMA on myeloma cells and CD3 on T cells, bringing them into proximity to activate and redirect cytotoxic T cells to kill BCMA‑expressing tumor cells (e.g., via immune synapse formation and perforin/granzyme release).
The BCMA×CD3 bispecific engages T cells via CD3 and binds BCMA on target cells, forming an immune synapse and activating T-cell cytotoxicity (perforin/granzyme-mediated lysis) against BCMA-expressing cells.
Elranatamab (Elrexfio) is a BCMA×CD3 bispecific antibody that redirects T cells to BCMA-expressing myeloma cells to mediate cytotoxicity.
Elranatamab is a bispecific antibody that simultaneously binds CD3 on T cells and BCMA on malignant plasma cells, cross-linking T cells to tumor cells to trigger T-cell activation and cytotoxic killing of BCMA-expressing myeloma cells.
Elranatamab bridges CD3 on T cells to BCMA on target cells, activating T cells to kill BCMA+ cells via perforin/granzyme-mediated cytotoxicity and apoptosis.
An off-the-shelf, full-length bispecific T-cell–engaging antibody that binds BCMA on malignant plasma cells and CD3 on T cells to redirect cytotoxic T cells against multiple myeloma cells.
Bispecific humanized monoclonal antibody that binds BCMA on malignant plasma cells and CD3 on T cells, cross-linking them to form an immune synapse, activate T cells, and redirect cytotoxic T-cell killing of BCMA-expressing myeloma cells.
Bispecific BCMA×CD3 engagement cross-links T cells to BCMA-expressing cells, forming an immune synapse and triggering perforin/granzyme-mediated T-cell cytotoxicity leading to apoptosis.